NKX3-1 and prostate carcinoma: Taken together, these studies suggest that TRPV2 and TRPM8 (along with NKX3.1) may constitute a valuable immunohistochemical panel to diagnose prostate cancer, and may identify patients at risk of aggressive disease who need early therapeutic intervention (as opposed to watchful waiting).